Formycon (XTRA:FYB) Stock Can Small Profit Hold Up Against Cash Strain?

Formycon stock closed at €18.56 on Thursday after a choppy few months, with the share price roughly flat over 30 days and slightly weaker over 90 days. The market reaction looks muted compared with what just landed in the earnings. Revenue for Q2 2026 came in at €12.663m and the company swung to a small net profit of €0.372m, helped by a sharp improvement in adjusted earnings before interest, tax, depreciation and amortisation. The key question now is whether traders are underpricing that profit inflection.

Love Formycon’s move back into profit, but unsure if this small gain offsets your concerns about earnings quality and balance sheet strength? Compare it with stocks that screen well for both profitability and resilience in our list of solid balance sheet and fundamentals stocks (429 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: €12.663m vs. €3.697m (very large increase from a low base)
• Net Income, Q2 2026 vs. Q2 2025: profit of €0.372m vs. loss of €31.392m (swing into profit)
• Basic EPS, Q2 2026 vs. Q2 2025: not disclosed for Q2 2026 vs. loss of €1.77713 per share (Q2 2025)
• Trailing 12-month Net Income, Q2 2026 vs. Q2 2025: loss of €25.132m vs. loss of €169.77m (loss materially reduced over the year)

Prefer clear visuals instead of scrolling through another wall of earnings tables and PDF footnotes? See Formycon’s full financial picture, including a concise breakdown of its recent earnings and revenue mix, in the interactive company report for Formycon.

Formycon bull case hinges on guidance and capital relief

Bulls argue that Formycon’s confirmed 2025–26 revenue guidance and the Phase III waiver for FYB206 have shifted the earnings profile toward profitable growth. The latest numbers partly back this up. H1 2026 revenue nearly tripled and adjusted EBITDA loss improved from €19.2m to €6.9m, which supports the claim that the cost base is scaling more slowly than revenue. FYB206 now contributes more than 40% of revenue, mainly from partnership milestones, which aligns with the thesis that capital is being recycled from late stage trials into commercialization. However, profitability is still fragile. The group only delivered a small Q2 net profit of €0.372m and cash declined to €51.8m as working capital absorbed funds. The earnings improvement story is real, but it is early and still heavily dependent on milestone recognition.

Bear case tests reliance on milestones and legal overhangs

Bears focus on U.S. biosimilar volatility, legal risk on FYB206 and the quality of earnings. The H1 2026 print gives them mixed evidence. Revenue is heavily skewed to FYB206 partnership milestones, and management itself flags non linear revenue timing. That backs concerns that earnings may be lumpy rather than driven by steady prescription volumes. Cash fell from €68.8m to €51.8m while receivables and working capital climbed, which fits the worry that reported profit does not fully translate into cash. Management also highlights a complex IP and litigation backdrop for FYB206 and slower than hoped royalty growth for FYB202. On the other hand, the equity ratio of about 54% and reduced trailing 12 month loss of €25.132m versus €169.77m a year earlier challenge the idea of a stressed balance sheet.

Compare Formycon’s internal profit inflection and reliance on milestones with how institutional analysts see the risk reward. See the consensus price target analysis for Formycon to check where the current targets sit after this earnings release.

Stay Ahead With Simply Wall St

If Formycon’s swing back to a small profit and reliance on milestones has your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch how the earnings story develops. Once you decide to take a position, use the Portfolio Command Center to cut through noise and stay focused on material updates that matter to your holdings. For a longer term view, tap into crowd wisdom and compare your thesis with thousands of other investors through the Community. By surfacing potential catalysts and risks early, you can stay informed about the market and make more confident decisions.

Seeking Alternatives Beyond Formycon Today

Fresh ideas can move fast. Some stocks are building quiet breakout momentum while they are still under the radar for now. Check these before the data goes stale and get in early.

• Spot companies riding the next wave of AI infrastructure demand by scanning the curated 55 AI infrastructure stocks before the crowd catches the strongest momentum shifts.
• Track potential income workhorses that aim to keep payouts flying with resilient balance sheets through the hand picked 440 dividend fortresses while yields still look attractive.
• Hunt for under the radar opportunities where fundamentals and sentiment have not yet been fully caught by the market using the focused 585 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com